Cognision and SOMNOmedics Partner to Enhance Sleep Biomarkers in Clinical Trials

Cognision has announced a strategic partnership with SOMNOmedics to advance sleep biomarkers in pharmaceutical clinical trials, announced in a press release. This collaboration will see Cognision integrating SOMNOmedics' next-generation polysomnography (PSG) solutions into its offerings, specifically designed for the rigorous demands of pharmaceutical-sponsored clinical trials.

The partnership combines Cognision's expertise in neurophysiological assessments with SOMNOmedics' compact and mobile PSG technology. This integration aims to provide an end-to-end solution for sponsors requiring precise sleep architecture data in therapeutic trials. The collaboration will enable the integration of robust sleep biomarkers into trials for drugs treating abnormal sleep conditions or those that may interfere with healthy sleep.

SOMNOmedics' PSG systems are recognized for their signal quality and adaptability, suitable for both inpatient and home use, which supports decentralized clinical trials. All PSG data will be managed within Cognision's cloud-based Clinical Trial Data Management System, offering near real-time access for sponsors to facilitate faster decision-making and adaptive trial designs.